Recordati Rare Diseases

Mohamed Ladha, President and General Manager of Recordati Rare Diseases, discusses the company’s involvement in the rare disease community.
Recordati Rare Diseases operates under the goal of maximizing the quality of life for rare disease patients through investments in research and education. From financial support for patients currently on their products to education opportunities for allied healthcare workers, the company offers a variety of services.
Therapeutic areas of focus for the company include Cushing’s and acromegaly in the endocrinology space, idiopathic multicentric Castleman disease (IMCD) and ongoing expansion into pediatric neuroblastoma in the oncology space, and inherited metabolic disorders including cystinosis, acute intermittent porphyria, N-acetylglutamate synthase (NAGS) deficiency, and cystinuria.
Recordati Rare Diseases also partners with patient advocacy groups to raise awareness for clinical trials and help them get involved. Some studies that the company is currently working on were presented at ENDO 2024, including real world evidence studies from the LINC6 study testing the safety and efficacy of osilodrostat in patients with endogenous Cushing’s syndrome, and LINC7 testing the safety and efficacy of osilodrostat in patients with non-Cushing’s disease Cushing’s syndrome.
Chapters:
Recordati's Goal 00:00
Disease Specialties 2:24
Clinical Trial Involvement 4:48